3 results
See protocol page 9This study designed to determine, via continuous monitoring with the Reveal XT implantable cardiac monitor (ICM) or newer approved version, the incidence of atrial fibrillation (AF) in patients suspected to be at high risk for…
Medtronic, Inc. is sponsoring the SMART Trial, a prospective, multi-center, international, randomized controlled, post-market trial. The purpose of this trial is to generate clinical evidence on valve safety and performance of SE versus BE TAVR in…
The objective of the present pilot study is to assess the incidence of sustained VA in 3 CTO groups: patients with successful percutaneous CTO recanalization (group A), patients with failed percutaneous CTO recanalization (group B), and patients…